Fatih Güzel

Fatih Güzel

Auto-generated profile, based on publicly available information

Fatih Güzel

Dicle University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2026 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
FGFatih Güzel
Fatih Güzel
HKHalil Kömek
Halil Kömek
NANalan Alan
Nalan Alan
CCCanan Can
Canan Can
MGMehmet Güven
Mehmet Güven
LKLevent Kabasakal
Levent Kabasakal

1 January 2025 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
FGFatih Güzel
Fatih Güzel
ŞTŞadiye Altun Tuzcu
Şadiye Altun Tuzcu
BTBekir Taşdemir
Bekir Taşdemir
SUMMARY OBJECTIVE: In daily practice, 18F-fluorodeoxyglucose positron emission tomography/computed tomography plays a crucial role in the clinical follow-up to evaluate treatment response and detect recurrence in patients with elevated serum tumor markers. In this research, we aimed to elucidate whether there was a correlation between markers and semiquantitative-metabolic parameters. METHODS: In this study, 66 patients who applied to our institution with a histopathological diagnosis of colorectal carcinoma and had two consecutive 18F-fluorodeoxyglucose positron emission tomography/computed tomography scans for diagnosis or response to treatment were enrolled. The obtained images were evaluated based on response evaluation criteria in solid tumors and positron emission tomography response criteria in solid tumors criteria. The patients were divided into two groups: regression patient group (n=45) and progression patient group (n=21). RESULTS: There was a high positive correlation between whole body-total lesion glycolysis and serum tumor marker (r=0.618, p=0.000), a moderate positive correlation between SUVmax (standardized uptake value) and primary tumor-total lesion glycolysis and serum tumor marker (r=0.497, p=0.001; r=0.511, p=0.000), and a weak positive correlation between SUVmean and whole body-metabolic tumor volume and serum tumor marker (r=0.435, p=0.003) in patients achieving regression. There was a moderate positive correlation between whole body-total lesion glycolysis and tumor marker in the progression group (r=0.596, p=0.004) and a weak positive correlation between SUVmax, SUVmean, total lesion glycolysis, whole body-metabolic tumor volume, and tumor marker in the progression group (r=0.343, p=0.128; r=0.299, p=0.188; r=0.279, p=0.220; r=0.374, p=0.095). CONCLUSION: We concluded that 18F-fluorodeoxyglucose positron emission tomography/computed tomography will provide beneficial outcomes in evaluating treatment response and detecting recurrent disease in patients with colorectal carcinoma. In this context, the whole body-total lesion glycolysis value is the most sensitive parameter that can be an alternative to SUVmax in predicting treatment response.

1 January 2024 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
ŞTŞadiye Altun Tuzcu
Şadiye Altun Tuzcu
IKİhSan Kaplan
İhSan Kaplan
IIİbRahim İbIloğlu
İbRahim İbIloğlu
AUAli Uyar
Ali Uyar
FGFatih Güzel
Fatih Güzel
BTBekir Taşdemir
Bekir Taşdemir
This study aimed to determine the thoracic and extra-thoracic extension of the disease in patients diagnosed with lung cancer and who had whole-body F18-fluorodeoxyglucose positron emission tomography/CT imaging and to investigate whether there is a relationship between tumor size and extrathoracic spread.

30 April 2024 in Journal of Medicine and Palliative Care
Verified
Journal Article
Open access
PDF file
ŞTŞadiye Altun Tuzcu
Şadiye Altun Tuzcu
IÇİlbey Erkin Çetin
İlbey Erkin Çetin
FGFatih Güzel
Fatih Güzel
EÇErdal Çetinkaya
Erdal Çetinkaya
BTBekir Taşdemir
Bekir Taşdemir
HBHüseyin Büyükbayram
Hüseyin Büyükbayram
Aims: Microsatellite instability has been determined as an important indicator in selecting chemotherapy drugs in colorectal cancer. Within the scope of this research, we aimed to elucidate the pathology reports and determine whether the metabolic parameters detected by PET/CT differ in MSI-positive and negative patients. Methods: A total of 35 patients were analyzed retrospectively. The patient population consisted of patients who applied to the Nuclear Medicine Department with a diagnosis of colon or rectum cancer, underwent PET/CT imaging for staging purposes, and were operated on. Results: A total of 35 colon or rectum cancer patients were included in this retrospective analysis. When microsatellite instability was analyzed among the patients, it was found that female patients comprised 4 microsatellite instability-positive and 16 microsatellite instability-negative individuals. On the other hand, 5 of the males were microsatellite instability positive, and 10 were microsatellite instability negative. The mean SUVmax value was 16.4±8.2, SUVmean was 8.1±1.9, TLG was 392.4±520.8, and MTV was 26.5±25.4 in the microsatellite instability-positive individuals. On the other hand, the mean SUVmax value was 22.7±9.7, SUVmean was 5.2±2.2, TLG was 316.4±325.7, and MTV was 21.7±21.7 in the microsatellite instability-negative individuals. Conclusion: With the advancement of image analysis technology, MTV, and TLG, volumetric indexes derived from 18F-FDG PET have been proposed for risk stratification of cancer patients. Regarding the outcomes of this research, the semiquantitative and metabolic parameters obtained by PET/CT are not different in colorectal cancer cases with instable and stable microsatellites.

24 September 2021 in Anatolian Current Medical Journal
Verified
Journal Article
Closed access
PDF file
ŞAŞadiye Altuntuzcu
Şadiye Altuntuzcu
BTBekir Taşdemi̇r
Bekir Taşdemi̇r
IKİhsan Kaplan
İhsan Kaplan
AUAli Uyar
Ali Uyar
FGFatih Güzel
Fatih Güzel
MDMansur Dağgülli̇
Mansur Dağgülli̇
Aim: PSMA expression has been observed in increased levels in patients with high Gleason scores. Current information on Ga-68 PSMA PET/CT shows that primary staging with PET/CT is important in patients with high-risk PC. Ga-68 PSMA PET/CT may also have a place in patients with intermediate risk PC, but only a few data are available at present. In this study, we aimed to elucidate the relationship between PSMA expression value in the prostate gland, total PSA levels and GS in patients diagnosed with prostate cancer. Material and Method: A total of 98 patients who were pathologically diagnosed with prostate cancer that did not receive any treatment and underwent Ga‐68 PSMA PET/CT imaging for staging were included in the study. Findings detected in Ga‐68 PSMA PET/CT imaging were categorized as prostate, lymph node, bone, and visceral organ. The focal increased PSMA expression values ​​observed in the prostate gland were recorded as SUVmax. The patients were divided into two separate groups according to their GS score (GS>7 and GS≤7). Correlations between prostate PSMA SUVmax, GS score and total PSA scores were investigated. Results: PSMA SUVmax levels of the group with a Gleason score of >7 were found to be significantly higher than the group with a Gleason score of ≤7 (p=0.03). The rates of lymph node metastasis, bone metastasis and visceral organ metastases were found to be significantly higher in the group with a Gleason score >7 compared to the group with a Gleason score ≤7. A positive correlation was observed between PSMA SUVmax and Total PSA (r=0.260, p=0.01). A positive correlation was observed between PSMA SUVmax and Gleason score (r=0.260, p=0.01). A positive correlation was observed between total PSA and Gleason score (r=0.320, p=0.001). Conclusion: In conclusion, PSMA SUVmax and Total PSA levels were higher in the group with high Gleason score. There is a positive correlation between PSMA SUVmax and total PSA. Clinicians should be careful in this regard, as the possibility of metastasis will be high in groups with high Gleason scores.

24 September 2021 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
ŞAŞadiye Altuntuzcu
Şadiye Altuntuzcu
FGFatih Guzel
Fatih Guzel
AUAli Uyar
Ali Uyar
IKİhSan Kaplan
İhSan Kaplan
YGYunus Güzel
Yunus Güzel
KYKendal Yalçin
Kendal Yalçin
Aim: Non-alcoholic fatty liver disease is one of the most common causes of liver disease worldwide with an estimated prevalence of 20%–30% in adult population. Following the widespread utilization of PET in the evaluation of malignant diseases, F-18 FDG have also been reported to be used in non-malignant processes. The aim of this study is to elucidate whether the FDG SUVmax values determined by PET/CT in different adipose tissue samples and the liver change according to NAFLD score. During our desktop research we did not find any published article therefore, it is the first study in this field. Materials and Method: A total of 230 patients who applied to Dicle University Faculty of Medicine, Department of Nuclear Medicine between March and April 2020 and who have been conducted FDG PET/CT for diagnosis, staging, restaging and evaluation of response to treatment were included in the study. Patients were divided into three groups according to their NAFLD score as patients with fibrosis score 0.676 (severe fibrosis group) group-3. Results: Liver SUVmax levels were found to be significantly higher in group-3 than group-1. No significant difference was observed between group-2 and group-3. SUVmax levels measured from supracalvicular region, posterior scapular region and mesentery region were not different from each other in all three groups. Glucose-corrected liver SUVglu levels were found to be significantly lower in group-1 than group-3 (p=0.001). In terms of liver SUVglu levels, group-1 and group-2 and group-2 and group-3 did not differ statistically from each other. Supracalvicular SUVglu, posterior scapular SUVglu and mesenteric SUVglu groups were not different from each other. Conclusions: The most important result of this study could be elaborated with increased FDG uptake in NAFLD. Liver FDG uptake increases as the severity of NAFLD increases as demonstrated by the NAFLD score.